Merck & Co. Inc., MRK is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, Merck & Co. Inc., MRK has a market cap of 162445.44. Since its IPO date on the 1/2/1970, Merck & Co. Inc., MRK performance year to date is 12.75%. Today Merck & Co. Inc., MRK has gained -0.44%, with a current price of 58.31.
Ownership of the company is 0.04% for insider ownership while institutional ownership is 74.90%. The management of the company have seen the company have a payout ratio of 110.40%. Return of assets are at 4.60%, with return on investment at 6.40%.
In terms of debt levels and profit levels, Merck & Co. Inc., MRK is seeing a long-term debt/equity of 0.54. While Total debt/equity is 0.59. With a profit margin of 11.70%, this is combined with a gross margin of 62.80%, and operating margin of 18.20%. Merck & Co. Inc. ability to meet debt levels, with a current ratio of 1.6, while the quick ratio is 1.3.
For the last year Merck & Co. Inc., MRK has seen a EPS growth of -61.60%. A performance for the year of 5.53%. The 52-week high is -2.74%, and the 52-week low is 32.03%. The average volume for Merck & Co. Inc., MRK is 3139032.
With a target price of 61.85, can Merck & Co. Inc., MRK reach this target? Looking at the value indicators of Merck & Co. Inc., MRK. Merck & Co. Inc. has a P/E of 35.82 and a forward P/E of 15.62. Perhaps the more useful indicator than P/E, is PEG which has a value of 7.03. Merck & Co. Inc. also has a P/S and a P/B of 4.12 and 3.71 respectively. For P/cash, Merck & Co. Inc. has a value of 12.55, while it is 27.91 for P/free cash flow.
At the current price of 58.31, Merck & Co. Inc. has a dividend yield of 3.14%. We see a return on equity of 10.20%.
Looking more long-term Merck & Co. Inc., is projected to get an EPS growth for the next five years of 5.10%. In the short-term an EPS growth of 0.81% in the next year is forecasted. This is after a EPS growth of -61.60% for this year and for the last five years a 41.50% growth has been seen.